title: Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
abstract: Recombinant fusion protein containing domain III of the dengue envelope protein fused to capsid protein from dengue 2 virus was immunogenic and conferred protection in mice against lethal challenge in previously report. Here, the antigenic specificity of this recombinant protein using anti-dengue antibodies from mice and humans and the cross-reactive humoral and cellular response induced in immunized mice were evaluated. The homologous anti-dengue antibodies showed a higher reactivity to the recombinant protein compared to the wide cross-reactivity observed for viral antigen as determined by ELISA. The IgG anti-dengue and functional antibodies, induced by the recombinant proteins in mice, were highly serotype specific by ELISA, hemaglutination inhibition and plaque reduction neutralizing tests. Accordingly, the cellular immune response determined by the IFNγ and TNFα secretion, was serotype specific. The specificity of serotype associated to this recombinant protein in addition to its high antigenicity, immunogenicity and protecting capacity suggest its advantage as a possible functional and safe vaccine candidate against dengue in a future tetravalent formulation.
authors.affiliation: PAHO/WHO Collaborating Center for the Study of Dengue and its Vector, Department of Virology, Tropical Medicine Institute "Pedro Kourí"-IPK, Autopista Novia del Mediodía Km 6½, P.O. Box 601, Marianao 13, Havana, Cuba.
authors.forename: Alienys
authors.initials: A
authors.lastname: Izquierdo
authors.forename: Iris
authors.initials: I
authors.lastname: Valdés
authors.forename: Lázaro
authors.initials: L
authors.lastname: Gil
authors.forename: Lisset
authors.initials: L
authors.lastname: Hermida
authors.forename: Sheila
authors.initials: S
authors.lastname: Gutiérrez
authors.forename: Angélica
authors.initials: A
authors.lastname: García
authors.forename: Lidice
authors.initials: L
authors.lastname: Bernardo
authors.forename: Alekis
authors.initials: A
authors.lastname: Pavón
authors.forename: Gerardo
authors.initials: G
authors.lastname: Guillén
authors.forename: María G
authors.initials: MG
authors.lastname: Guzmán
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D003429:Cross Reactions; D003715:Dengue / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000008:administration & dosage / Q000276:immunology*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D016019:Survival Analysis; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D010948:Viral Plaque Assay
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D053059:Dengue Vaccines; C051821:E-glycoprotein, Dengue virus type 2; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D007371:Interferon-gamma